Autogene cevumeran
Vaccine
Also known as RG6180, RO7198457
Evidence outlook
Pancreatic Ductal Adenocarcinoma: mid-stage studies underway, no completed readout
In Pancreatic Ductal Adenocarcinoma, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.
Development in Colorectal Cancer stopped (2026-08) after a negative readout. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Pancreatic Ductal Adenocarcinoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Autogene Cevumeran: this drug | Phase 2 | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| Daraxonrasib (Rasonque) | Approved | Small molecule | pan-RAS, RAS (pan-RAS, RAS-mutant tumors) | Partial signal | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| INCB161734 | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Quemliclustat | Phase 3 | Small molecule | CD73 (NT5E) | not yet graded | No reviewed efficacy summary in this indication | |
| Setidegrasib | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Navlimetostat | Phase 2/3 | Small molecule | PRMT5 (protein arginine methyltransferase 5), MTA-cooperative binding | not yet graded | No reviewed efficacy summary in this indication | |
| ERAS-0015 | Phase 2 | Small molecule | pan-RAS | not yet graded | No reviewed efficacy summary in this indication | |
| GFH375 | Phase 2 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Nuzefatide Pevedotin | Phase 2 | Peptide | EphA2 | not yet graded | No reviewed efficacy summary in this indication | |
| ARV-806 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Vopimetostat | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK41959 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Autogene cevumeran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (1)
November 2027 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent